Development and Validation of Advanced Mammalian Models for Alzheimers Disease-Related Dementias (ADRD) (R61/R33 Clinical Trial Not Allowed)

The summary for the Development and Validation of Advanced Mammalian Models for Alzheimers Disease-Related Dementias (ADRD) (R61/R33 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Development and Validation of Advanced Mammalian Models for Alzheimers Disease-Related Dementias (ADRD) (R61/R33 Clinical Trial Not Allowed): This funding opportunity announcement (FOA) encourages research to develop, characterize and validate innovative mammalian models that recapitulate molecular, cellular, neuropathological, behavioral and cognitive hallmarks of the Alzheimers Disease-Related Dementias (ADRD), including Lewy body dementia (LBD), vascular contributions to cognitive impairment and dementia (VCID), frontotemporal degeneration (FTD) and mixed etiology dementias (MED). Models will be expected to exhibit a broad range of features characteristic of the dementia disorder being modeled, including a mid- to late-life onset consistent with the human disorder, multiple age-dependent neuropathological processes and the associated behavioral, cognitive and/or physiological abnormalities. For each proposed mammalian model, a relevant suite of phenotypes that inform human ADRD disease progression and mechanisms should be characterized across the full life span or, for longer-living mammalian models, throughout the disease-relevant stages of adulthood. The goal of this FOA is to establish multi-dimensional mammalian models for ADRD to serve as tools to interrogate molecular disease mechanisms and identify therapeutic targets.

Federal Grant Title:	Development and Validation of Advanced Mammalian Models for Alzheimers Disease-Related Dementias (ADRD) (R61/R33 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-19-167
Type of Funding:	Grant
CFDA Numbers:	93.233, 93.837, 93.838, 93.839, 93.853, 93.866
CFDA Descriptions:	Information not provided
Current Application Deadline:	March 14th, 2019
Original Application Deadline:	March 14th, 2019
Posted Date:	January 23rd, 2019
Creation Date:	January 23rd, 2019
Archive Date:	April 19th, 2019
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	January 23rd, 2019

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PAR-19-167.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional); • Cell and Gene Therapies for HIV Cure: Developing a Pipeline (P01 Clinical Trial Not Allowe...; • NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (...; • NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (...; • Predoctoral Training in Advanced Data Analytics for Behavioral and Social Sciences Researc...; • Ancillary Studies in Clinical Trials (R01); • Opportunity PA-08-021; • Research Demonstration and Dissemination Grants (R18)
More Grants from the National Institutes of Health: • The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Preven...; • Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional); • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...